Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MirZyme ADMA pathway small molecule
- Development stage
- Preclinical
- Lead developer
- MirZyme Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MirZyme ADMA pathway small molecule is an experimental small molecule therapeutic being developed by MirZyme Therapeutics for the treatment of preeclampsia and fetal growth restriction (FGR). The drug targets the asymmetric dimethylarginine (ADMA) pathway, which is a key regulator of vascular endothelial function. ADMA is an endogenous inhibitor of nitric oxide synthase (NOS); elevated levels of ADMA are associated with reduced nitric oxide bioavailability, leading to the hypertension and placental dysfunction characteristic of preeclampsia. By modulating this pathway—likely through the regulation of the enzyme dimethylarginine dimethylaminohydrolase (DDAH) which degrades ADMA—the therapeutic aims to restore endothelial nitric oxide production and improve maternal and fetal outcomes. The program is currently in the IND-enabling/pre-clinical stage of development.
- Other names
- ADMA pathway small moleculeSmall molecule (ADMA)
02
Targets
DDAH (Dimethylarginine dimethylaminohydrolase 1)
Beyond the preview
Go deeper on MirZyme ADMA pathway small molecule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MirZyme ADMA pathway small molecule.